Načítá se...
p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial
Standard molecular classification of endometrial cancers (EC) is now endorsed by the WHO and identifies p53-abnormal (p53abn) EC as the subgroup with the poorest prognosis and the most likely to benefit from adjuvant chemo(radio)therapy. P53abn EC are POLE wildtype, mismatch repair proficient and sh...
Uloženo v:
| Vydáno v: | Mod Pathol |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Nature Publishing Group US
2022
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7613653/ https://ncbi.nlm.nih.gov/pubmed/35752743 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41379-022-01102-x |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|